The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Know AML webinar | What are mutations, and why do they matter in AML?
Charles Craddock
May 20, 2025
Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charles Craddock, physician at Queen Elizabeth Hospital Birmingham and Know AML Ambassador, discussing mutations and why they matter in AML.
Professor Craddock opened the session by introducing himself along with fellow speakers, Gail J. Roboz, physician at Weill Cornell Medicine and Know AML Ambassador, and Ralph Hills, Know AML Chair, who shared his personal journey living with AML.
Professor Craddock began by outlining the discovery of DNA, the basics of genetics, and how mutations occur (Figure 1).
He then highlighted how mutation testing in AML helps to:
- Confirm diagnosis, as certain mutations such as CEBPA, FLT3, IDH1/2, and NPM1 are strongly associated with acute leukemia.
- Categorize mutations and identify AML subtypes, which can help estimate how a patient might respond to treatment and predict the likely course of the disease.
- Guide the use of targeted therapies designed to target a particular mutation, such as FLT3.
- Align with clinical guidelines, as the current recommendations for diagnosis and management of AML now state that the characterization of mutations that commonly occur in AML with a technique called next-generation sequencing is essential.
- Make decisions around whether a stem cell transplant would be suitable.
- Detect any low levels of disease that may remain after treatment.
This independent educational activity is supported by Thermo Fisher Scientific.
All content is developed independently by the faculty. The funder is allowed no influence on the content.
